Identification
Personal identification
- Full name
- Sofia Azambuja Duarte Santos Braga
Citation names
- Braga, Sofia
Author identifiers
- Ciência ID
- 3F1C-792B-93F2
Addresses
- José de Mello Saúde, Av. do Forte nº 3, Edif. Suécia III, piso 2 , 2790-073 , Carnaxide, Oeiras, Portugal (Professional)
Knowledge fields
- Medical and Health Sciences - Clinical Medicine - Oncology
Languages
Language | Speaking | Reading | Writing | Listening | Peer-review |
---|---|---|---|---|---|
English | Advanced (C1) | Advanced (C1) | Advanced (C1) | Advanced (C1) | |
Portuguese | Advanced (C1) | Advanced (C1) | Advanced (C1) | Advanced (C1) | |
French | Advanced (C1) | Advanced (C1) | Advanced (C1) | Advanced (C1) | |
Spanish; Castilian | Intermediate (B1) | Intermediate (B1) | Beginner (A1) | Intermediate (B1) |
Education
Degree | Classification | |
---|---|---|
2009 - 2014
Concluded
|
Programa de Formação Médica Avançada (Fundação Gulbenkian) (Doutoramento)
Universidade Nova de Lisboa Faculdade de Ciências Médicas, Portugal
"Clinical decisons in breast cancer a heterogenous disease" (THESIS/DISSERTATION)
|
Aprovado por unanimidade |
1992 - 1998
Concluded
|
Medicina (Mestrado integrado)
Universidade de Lisboa Faculdade de Medicina, Portugal
|
16 |
Affiliation
Teaching in Higher Education
Category Host institution |
Employer | |
---|---|---|
2016/01/01 - Current | Assistant Professor (University Teacher) | Universidade Nova de Lisboa Faculdade de Ciências Médicas, Portugal |
2009/03/01 - Current | Assistant Professor (University Teacher) | Universidade do Algarve - Campus de Gambelas, Portugal |
Others
Category Host institution |
Employer | |
---|---|---|
2023/03 - Current | Director Oncology Department | Hospital Professor Doutor Fernando Fonseca EPE, Portugal |
2016 - Current | Research Collaborator | Universidade Nova de Lisboa Faculdade de Ciências Médicas, Portugal |
2015/12/01 - Current | Consultant Oncologist | Hospital Professor Doutor Fernando Fonseca EPE, Portugal |
2014/11/01 - Current | Consultant Oncologist | Hospital de Vila Franca de Xira, Portugal |
2013/01/01 - Current | Scientific Director | Rede CUF, Portugal |
2013 - Current | Resident training program of the Medical Oncology Department | Hospital Professor Doutor Fernando Fonseca EPE, Portugal |
2015 - 2015 | Clinical Research | iNOVA4Health, Portugal |
2011/09/01 - 2012/12/31 | Staff Oncologist | Fundação Champalimaud, Portugal |
2006/07/23 - 2011/10/01 | Staff Oncologist | Instituto Português de Oncologia de Lisboa Francisco Gentil EPE, Portugal |
2000/01/01 - 2006/07/21 | Specialty training | Instituto Português de Oncologia de Lisboa Francisco Gentil EPE, Portugal |
2005/05/01 - 2006/06/30 | Clinical Research Fellow | Institut Jules Bordet, Belgium |
1998/01/01 - 2000/12/31 | General residency | Hospital de Santa Maria, Portugal |
Projects
Grant
Designation | Funders | |
---|---|---|
2019 - 2021 | Dissecting the predictive and therapeutic value of HLA-DR expressing T Lymphocytes in Breast Cancer.
Terry Fox Research Grant 2019
Researcher
Liga Portuguesa Contra o Cancro, Portugal
|
|
2019 - 2021 | HLA-DR+T cell subsets as biomarkers of breast cancer aggressiveness and patients’ response to neoadjuvant chemotherapy.
Tagus Tank Consortium- Research Prize in Medicine 2018
Researcher
Tagus Tank Consortium, Portugal
|
|
2016 - 2020 | Therapeutic Targets for Triple Negative Breast Cancer: Development of mono and bispecific antibodies against Notch1 ligands.
PTDC/BBB-BMD/4497/2014
Researcher
Fundação para a Ciência e a Tecnologia, Portugal
|
|
2016 - 2018 | Searching positive biomarkers in Triple negative breast cancer (TNBC)
UID/Multi/04462/2013-Lisboa-01-0145FEDER-007
Researcher
Fundação para a Ciência e a Tecnologia, Portugal
iNOVA4Health, Portugal |
|
2012 - 2014 | Centrosome abnormalities in breast cancer
Terry Fox Award 2012
Researcher
Liga Portuguesa Contra o Cancro, Portugal
|
Concluded
|
Other
Designation | Funders | |
---|---|---|
2021 - 2022/12 | Cracking the role and therapeutic value of novel CCR4+ low density neutrophils in breast cancer.
iNOVA4Health
Researcher
iNOVA4Health, Portugal
|
Outputs
Publications
Book chapter |
|
Conference poster |
|
Journal article |
|
Activities
Oral presentation
Presentation title | Event name Host (Event location) |
|
---|---|---|
2017/05 | Fifteen years of practice changing clinical trials in breast cancer | International Day of Clinical Trials
INFARMED (Lisboa, Portugal)
|
2017/03 | Breast Cancer Update 2016 | Update for Practicing Oncologists
European Society of Medical Oncology (Lisboa, Portugal)
|
2017/03 | Predictive value of breast cancer immune features in response to neoadjuvant chemotherapy | Inflammation Symposium
Centro de Estudos de Doenças Crónicas (CEDOC) (Lisboa, Portugal)
|
2017/03 | Inovação em Oncologia | Reunião Anual Sociedade Portuguesa Enfermagem Oncológica
Hospital de Braga (Braga, Portugal)
|
2016/11 | Are we ready for a National Molecular Screening Platform in metastatic breast cancer | Reunião SOLTI Portugal
Grupo Cooperativo Ibérico de Ensaios Clínicos em Carcinoma da Mama
|
2016/11 | O programa de ensaios clínicos do Instituto CUF de Oncologia, Investigação Clínica: do compromisso à ação | Reunião Apifarma |
2016/10 | Young Oncologists Career Management Session: Practicing Oncologist |
European Society for Medical Oncology
|
2016/10 | ESMO Lounge Session: How I use and access ESMO resources |
European Society for Medical Oncology
|
2016/10 | ESMO Lounge Session: Practicing Oncologists Committee |
European Society for Medical Oncology
|
2016/10 | Interview for Oncology PRO: Trastuzumab Biosimilars |
European Society for Medical Oncology
|
2016/10 | Breast Cancer Neoadjuvant Trials as a model to study drug resistance | iMED genetics workshop
NOVA Medical School
|
2016/10 | Espiritualdade e cancro |
Instituto CUF de Oncologia
|
2016/07 | Update in Clinical Oncology |
Instituto CUF de Oncologia
|
2016/05 | Fertilidade e Cancro | Congresso dos Médicos Internos da José de Mello Saúde
Hospital de Braga
|
2016/03 | Cancer and Inflammation | Programa de Doutoramento da NOVA Medical School
Universidade NOVA de Lisboa
|
2016 | Systemic therapy in Prostate Cancer |
Hospital de Vila Franca de Xira
|
2016 | Initiating the cancer genetic risk programme |
Hospital Fernando da Fonseca
|
2015 | Evaluation of symptoms of patients on palliative chemotherapy |
St. Olavs Hospital (Trondheim) (Trondheim, Norway)
|
2015 | What innovative tests should we use in breast cancer patients and why? | Meeting of hospital cancer genomics programs
King Albert II Institute Cancerology and Hematology, Cliniques Universitaires Saint-Luc, UCL Bruxelles (Bruxelas, Belgium)
|
2015 | Centrosome clustering in breast cancer | Annual meeting Biomedical students,Universidade Algarve
Universidade do Algarve
|
2015 | Hormonal replacement therapy in cancer survivors |
Hospital de Vila Franca de Xira
|
2015 | Developing breast cancer research in a clinical setting | Anual Meeting Portuguese Senology Society |
2015 | Predictive and prognostic factors in early breast cancer | Annual meeting Medical students, Universidade de Lisboa |
2015 | Initiation to research module: My PhD trajectory | Nova Medical School, PhD Program |
2015 | Gynecological Oncology the view of the oncologist | Annual Meeting Portuguese Society of Pathologists |
2015 | Cancer module - How I developed my PhD project | Porto Medical School, MD-PhD Program |
2015 | Immunology module - Cancer immunology | Lisbon Medical School, MD-PhD Program |
2014 | Biology of cancer bridging basic and translational research: Cytoskeletal dynamics in cancer | Center for Genomic Regulation - EU Life Consortium Scientific Meeting
(Barcelona)
|
2014 | When should we stop palliative chemotherapy | European Society for Medical Oncology
European Society for Medical Oncology
|
2014 | How to deliver bad news |
Hospitais CUF Lisboa
|
2014 | How to develop a research consortium - Our experience in H2020 | Annual innovation meeting José de Mello group |
2014 | How to deliver bad news |
Hospital CUF Porto
|
2014 | Personalized cancer therapy | Annual pharmaceutical sciences student retreat, Universidade do Porto
Universidade do Porto
|
2014 | How to deliver bad news |
Hospital Vila Franca de Xira
|
2014 | Ethics in the end of life | Encontros de Ciencia Viva, Universidade de Aveiro
Universidade de Aveiro
|
2014 | Centrosome clustering in breast cancer | Annual Meeting Portuguese Society of Oncology |
2014 | Shared session with Stein Kaasa on Building a H2020 research consortium to study palliative chemotherapy | Encontro de Cuidados Paliativos Instituto Português de Oncologia Porto
Instituto Português de Oncologia Porto
|
2013 | Chemotherapy in the end of life | Annual meeting of the Galician Lung Cancer Society
(Vigo, Spain)
|
2013 | Centrosome clustering is prognostic in early breast cancer | Annual meeting of the Portuguese Society of Human Genetics |
2013 | Centrosome clustering is prognostic in early breast cancer | Annual Gulbenkian PhD student retreat |
2013 | Highthroughput data module: How does a clinician do a PhD project in bioinformatics | PhD Program
Lisbon Nova Medical School
|
2013 | Initiating the cancer genetic risk programme |
Hospital CUF Descobertas
|
2013 | Neoadjuvant systemic treatment | Annual Meeting of Portuguese Senology Society |
2013 | How to foster collaboration between clinicians and bench scientists | Annual Breast Cancer Meeting of Centro Hospitalar Barreiro-Montijo
Hospital do Barreiro
|
2013 | Chemotherapy in the end of life | Palliative Care Meeting - Hospital CUF Porto
Hospital CUF Porto
|
2012 | Investigação em Oncologia | Jornadas de Carcinoma da mama do Hospital do Barreiro
Hospital do Barreiro
|
2011 | Heterogeneidade do carcinoma da mama triplo negativo | Reunião anual Astra Zeneca
Astra Zeneca
|
2011 | Centrosome clustering is prognostic in early breast cancer | Annual meeting of the Portuguese Society of Human Genetics |
2010 | Are all aromatse inhibitors created equal? | European breast cancer conference
(Barcelona, Spain)
|
2009/01 | Cancro da Mama: Diagnóstico e terapêutica | 4ª Reunião de cancro da mama do Serviço de Oncologia, Hospital do Barreiro
Hospital do Barreiro (Barreiro, Portugal)
|
2009 | Terapêutica Neoadjuvante | Congresso Nacional de Senologia
(Portugal)
|
2008 | Terapêutica endócrina em Carcinoma da Mama | Encontros de Oncologia do Serviço de Oncologia Hospital de Évora
Hospital de Évora (Évora, Portugal)
|
2007 | Tales of targeted therapy: Sunitinib | First Iberic Meeting on Medicinal Chemistry: Anticancer Agents
(Peso da Régua, Portugal)
|
2006 | The MINDACT patient DVD | MINDACT investigator meeting
European Breast Cancer Conference (Nice, France)
|
2006 | Tailoring of systemic therapy in early stage breast cancer: Any progress? | Apresentação oral, XVII International Congress of Anti-Cancer Treatment |
2005 | Better predictive factors in endocrine-responsive breast cancer than the estrogen receptor itself | Congresso da Sociedade Belga de Oncologia Ginecológica |
2004/05 | Percurso dos doentes oncológicos num Serviço de Medicina Interna |
X Congresso Nacional de Medicina Interna (Vilamoura, Portugal)
|
2001/05 | Infecções fúngicas num Serviço de Medicina | VII Congresso Nacional de Medicina Interna
(Vilamoura, Portugal)
|
Supervision
Thesis Title Role |
Degree Subject (Type) Institution / Organization |
|
---|---|---|
2017 - 2021 | Histopathological Prognostic Factors in Colon Retal Cancer After Curative Surgery - A 5 years Follow-Up
Co-supervisor
|
Doctoral Programme in Medicine (PhD)
Universidade Nova de Lisboa Faculdade de Ciências Médicas, Portugal
|
2016 - 2020 | Translating Breast Cancer Immune Features into Biomarkers and Therapies
Co-supervisor
|
International Doctoral Programme in Health Sciences (PhD)
Universidade Nova de Lisboa Faculdade de Ciências Médicas, Portugal
|
2016 - 2020 | Differential molecular signature in patients from African origin with Triple-Negative Breast Cancer
Co-supervisor
|
International Doctoral Programme in Health Sciences (PhD)
Universidade Nova de Lisboa Faculdade de Ciências Médicas, Portugal
|
2017 - 2018 | Avaliação da Expressão de PD-L1 e de Subpopulações Linfocitárias em Cancro da Mama
Supervisor
|
Mestrado em Oncobiologia e Mecanismos Moleculares do Cancro (Master)
Universidade do Algarve, Portugal
|
2017 - 2018 | Utilização de Imunohistoquímica para Avaliação da Densidade Linfática no Mesentério de Adenocarcinomas do Cólon
Supervisor
|
Mestrado em Oncobiologia e Mecanismos Moleculares do Cancro (Master)
Universidade do Algarve, Portugal
|
2015 - 2016 | Expression of matrix gla protein (MGP) in breast cancer: a molecular and cellular approach
Co-supervisor
|
Mestrado em Oncobiologia |
2014 - 2015 | Towards direct transdifferentiation of adult human cells to the pancreatic ß-cell fate
Co-supervisor
|
Mestrado em Ciências Biomédicas
Universidade do Algarve, Portugal
|
Event participation
Activity description Type of event |
Event name Institution / Organization |
|
---|---|---|
2020 - Current | Presentation of the Television Program "Histórias Clínicas" from the Saúde+TV |
Association member
Society Organization name | Role | |
---|---|---|
2017 - Current | European Medicines Agency | |
2015 - Current | European Society Medical Oncology | Oncology PRO Working group and Practicing Oncologists’ Committee |
2014 - Current | European Society Medical Oncology | Practicing Oncologists Committee |
2013 - Current | European Society Medical Oncology | Examination Working Group and Publishing Group |
2008 - 2009 | Member national panel on consensus in triple negative and lobular breast cancer - Portuguese Senology Society | |
2007 - 2009 | Secretary of the breast group in National Comission for Oncological Disease - Ministry of health | |
2006 - 2007 | Medical advisor - Pfizer |
Journal scientific committee
Journal title (ISSN) | Publisher | |
---|---|---|
2011 - Current | Annals of Oncology (1569-8041) | Elsevier |
Distinctions
Award
2023 | CaixaImpulse Innovation Grant 2023
Fundação 'la Caixa', Portugal
|
2019 | Terry Fox Award - Dissecting the predictive and therapeutic value of HLA-DR-expressing cytotoxic T lymphocytes in Breast Cancer
Liga Portuguesa Contra o Cancro, Portugal
|
2019 | Pfizer Award - HLA-DR in Cytotoxic T Lymphocytes Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
Pfizer Portugal, Portugal
|
2018 | Tagus Tank Consortium - HLA-DR in Cytotoxic T Lymphocytes Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
Tagus Tank Consortium, Portugal
|
2016 | Leaders Generation Programme
European Society for Medical Oncology, Switzerland
|
2016 | Development of therapeutics targeting Notch1 ligands Delta-like1 and Jagged2
iNOVA4Health, Portugal
|
2016 | Searching for positive markers in triple negative breast cancer
iNOVA4Health, Portugal
|
2014 | Norwegian National Science Foundation - Collaborative research grant: Cancer Care in the End of Life |
2014 | Collaborative grant Centrosome abnormalities in breast cancer
Fundação para a Ciência e a Tecnologia, Portugal
|
2014 | Collaborative research grant: Notch ligands in Triple Negative Breast Cancer
Fundação para a Ciência e a Tecnologia, Portugal
|
2013 | QREN Award - Generating patient derived effector cells in breast cancer patients |
2013 | Immunotherapy in breast cancer
Bluepharma, Portugal
|
Other distinction
2012 | Terry Fox Award - Centrosome abnormalities in breast cancer
Liga Portuguesa Contra o Cancro, Portugal
|
2011 | Award for best presentation at the annual meeting of Gulbenkian Students
Instituto Gulbenkian de Ciência, Portugal
|
2008 | 3rd place: Consultation of family risk of breast and ovary, IPO Lisboa |
2008 | Advanced medical education program
Fundação Calouste Gulbenkian, Portugal
Fundação Champalimaud, Portugal |